Click Here to return To Results

 

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis NEJM 376:221-234,280, Hauser, S.L.,et al, 2017 See this aricle in Pubmed Article Abstract Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta-1a over a period of 96 weeks. Larger and longer studies of the safety of ocrelizumab are required.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction B cell lymphocytes carcinoma carcinoma of breast complications efficacy herpes virus infection infection interferon beta 1-a MRI,abnormal multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of ocrelizumab prevention of neurologic disorders safety treatment of neurologic disorder viral infection,reactivation

Click Here to return To Results